OPsumit USers Registry

Not Recruiting

Trial ID: NCT02126943

Purpose

Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.

Official Title

US-based, Observational, Drug Registry of Opsumit® (Macitentan) New Users in Clinical Practice

Stanford Investigator(s)

Roham Zamanian
Roham Zamanian

Professor of Medicine (Pulmonary and Critical Care Medicine)

Eligibility

Inclusion Criteria:

Patients newly treated with Opsumit defined as a new user of therapy, initiated ≤ 30 days prior to enrollment visit.

Signed ICF

Exclusion Criteria:

Previous user of Opsumit defined as patient who initiated therapy \>30 days prior to enrollment.

Patients enrolled in any ongoing clinical trials

Intervention(s):

drug: Opsumit (macitentan)

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305